SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors digest record revenue growth and a strong cash position alongside ongoing speculation regarding global commercial expansion and upcoming FDA regulatory catalysts. The community is actively debating the company's long-term fundamentals versus short-term price volatility, with many expressing strong conviction in the firm's pipeline despite heavy short interest.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and intense community debate as investors react to its slide toward 52-week lows ahead of upcoming quarterly earnings. While the bullish community is highlighting strong product demand, successful international expansion, and the ongoing integration of the Alani Nu brand, bears are expressing concerns over slowing core brand momentum, margin pressure from commodity costs, and increased private-label competition.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is driving intense community debate following a mixed shelf offering filing and a rollercoaster earnings reaction that saw the stock swing violently between gains and losses. Investors are divided between those citing massive revenue growth, buyback strength, and AI-driven efficiency as a generational buying opportunity and those concerned by high intraday volatility and the potential for dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor interest following a strong first-quarter earnings report that featured a notable EPS beat and raised full-year net income guidance. The community is actively discussing the stock's potential for a breakout, driven by its underlying profitability, expanding institutional partnerships, and high short interest that has sparked speculation about a possible short squeeze.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is facing significant investor frustration as earnings performance is overshadowed by concerns over executive leadership and disappointing commentary regarding future sales. Community sentiment is deeply divided, with many traders criticizing management's transparency while bargain hunters view the recent sell-off as an opportunity to accumulate shares at perceived value.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility following an unexpected FAERS report regarding a patient death, which sparked a sharp sell-off before a rapid recovery as the event was deemed unrelated to their treatment. The community remains deeply divided, with bulls pointing to the company's strong revenue and upcoming pipeline readouts as catalysts for a potential short squeeze, while bears continue to highlight regulatory skepticism and skepticism toward the efficacy of their flagship therapy.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is surging following a strong quarterly earnings report that featured a revenue beat and robust growth in its high-value customer base, signaling to investors that demand for AI-driven cloud monitoring remains resilient. While some traders are expressing caution after the significant price jump, the broader community sentiment is focused on the stock's role as a key infrastructure player in the expanding AI ecosystem.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending following a report positioning the company as a key supplier for AI infrastructure, specifically regarding co-packaged optics components for major tech industry players. The community is actively debating the sustainability of this price action, with many closely tracking significant spikes in trading volume and options activity ahead of key industry conferences.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul, with new CEO and largest shareholder Kevin Tang taking the helm to drive strategy and prioritize shareholder value. The community is actively discussing the recent acquisition of Kezar Life Sciences and the potential for a strategic buyout, fueling optimistic speculation about the company's future direction.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics is trending after receiving a second Complete Response Letter from the FDA for its tabelecleucel therapy, sparking intense debate among retail traders regarding its financial runway and the potential for a long-term turnaround via a Type A meeting path. While some community members view the stock as a distressed asset facing inevitable dilution, others are actively scouting for entry points, citing the drug's established approval in Europe and the possibility of a strategic partnership or buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PetMed Express (NASDAQ:PETS) Shares Cross Above Two Hundred Day Moving Average - What's Next?

PetMed Express (NASDAQ:PETS) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell...

PetMed Express (NASDAQ:PETS) Share Price Passes Above 200-Day Moving Average - Here's Why

PetMed Express (NASDAQ:PETS) Shares Pass Above 200 Day Moving Average - Here's Why...

PetMed Express (NASDAQ:PETS) Announces Earnings Results, Misses Estimates By $0.44 EPS

PetMed Express (NASDAQ:PETS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.06...

PetMed Express (NASDAQ:PETS) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

PetMed Express (NASDAQ:PETS) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened...

Short Interest in PetMed Express, Inc. (NASDAQ:PETS) Decreases By 60.9%

PetMed Express, Inc. (NASDAQ:PETS - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed...

PetMed Express (NASDAQ:PETS) Shares Cross Above 200 Day Moving Average - What's Next?

PetMed Express (NASDAQ:PETS) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened...

PetMed Express, Inc. (NASDAQ:PETS) Short Interest Update

PetMed Express, Inc. (NASDAQ:PETS - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 2,698,921...

PetMed Express (NASDAQ:PETS) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?

PetMed Express (NASDAQ:PETS) Stock Price Passes Above 200 Day Moving Average - Here's What Happened...

PetMed Express, Inc. markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. The firm provides treatments for allergies, arthritis, anxiety, dermatitis, diabetes, and heartworms. It offers access to a range of non-prescription health and wellness products and Rx food, non-Rx food, and treats. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Petmed Express, Inc.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.18	--	--	N/A
Q3 '25	-$0.06	--	--	N/A
Q2 '25	$0.04	--	--	N/A
Q1 '25	-$0.06	-$0.07	-16.67%	MISSED
Q4 '24	-$0.34	--	--	N/A

PETS
Petmed Express, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest PETS News

PETSPetmed Express, Inc.